Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Matthew McGuirk, Asma Zakir, Al-Ola Abdallah, Nausheen Ahmed, Sunil Abhyankar, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 173.

https://doi.org/10.1182/blood-2025-173

Published: 2025

Journal Articles

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Yuanli Lei, Muhammad Atif Khan, Aqsa Ashraf, Noha Soror, Muhammad Salman Faisal, Jennifer Holter-Chakrabarty, Adam Asch, Forat Lutfi, Rachel Dileo, Sami Ibrahimi, Manu Pandey, Mohamad Khawandanah, Silas Day, Huimin Wu, Prerna Mewawalla, Nausheen Ahmed, Taha Al-Juhaishi

Blood (2025) 146 (Supplement 1): 2373.

https://doi.org/10.1182/blood-2025-2373

Published: 2025

Journal Articles

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

Muhammad Atif Khan, Zafar Ali, Abat Khan, Faiza Humayun Khan, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2025-7841

Published: 2025

Journal Articles

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Raeef Rahman, Isuru Ratnayake, Jianzheng Wu, Lauren Scott, William Wesson, Razan Mansour, Marc Hoffmann, Aung Tun, Joseph Bennett, Al-Ola Abdallah, Muhammad Mushtaq, Dinesh Mudaranthakam, Joseph McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 7630.

https://doi.org/10.1182/blood-2025-7630

Published: 2025

Journal Articles

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

Paul Worsley, Jianzheng Wu, Isuru Ratnayake, Dinesh Mudaranthakam, Al-Ola Abdallah, Jeries Kort, Evguenia Bhurtel, Leyla Shune, Joseph McGuirk, Muhammad Nashatizadeh, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2025-2389

Published: 2025

Journal Articles

The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective

Neda Amirmokhtari, Jianzheng Wu, Marc Hoffmann, Aung Tun, Joseph Bennett, Nausheen Ahmed, Muhammad Umair Mushtaq, Shaun DeJarnette, Forat Lutfi

Blood (2025) 146 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2025-7197

Published: 2025

Journal Articles

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Blood (2025) 146 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2025-1798

Published: 2025

Journal Articles

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 8075.

https://doi.org/10.1182/blood-2025-8075

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Rachel Dileo, Prerna Mewawalla, Gina Patrus, Christopher Strouse, Ethan Chen, Hira Shaikh, James A Davis, Kimberly M Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2024-206059

Published: 2024

Journal Articles

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Fathima Shehnaz Ayoobkhan, Sara Shatnawi, Moazzam Shahzad, Aqeeb Ur Rehman, Sohaib Irfan, Raabia Qureshi, Arooq Khalid, Sibgha Gull Chaudhary, Faiz Anwer, Briha Ansari, Joseph P. McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 5045.

https://doi.org/10.1182/blood-2024-203904

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 4921.

https://doi.org/10.1182/blood-2024-199289

Published: 2024

Journal Articles

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Barry Skikne, Tara L. Lin, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Omar Alkharabsheh, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2024-205757

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only